We are IQVIA, The Human Data Science Company

Healthcare is an industry designed to help humans. As a global community, we continuously invest and commit to advancing human health. To deliver value and real outcomes. To rise to the challenge to find the next breakthrough by making the most of increasingly limited resources.

We are inspired by the potential and propelled by the possibilities. We share the vision to drive healthcare forward. To see how we can help accelerate progress and achievements. Others are developing these medical breakthroughs.  We do our part by using breakthroughs in insights, technology and human intelligence to reimagine and deliver ways to help make them a reality.

It’s bigger than better clinical trials.  Or advances in technologies and analytics.  Or faster insights.  It’s about unleashing the power of human data science.  And that is why IMS Health and Quintiles have come together to be IQVIA, The Human Data Science Company.

Motivated by the industry we help, we’re committed to providing solutions that enable life sciences companies to innovate with confidence, maximize opportunities, and, ultimately, drive human health outcomes forward.

Our Difference

Unparalleled data; insightful and actionable analytics; advanced technology; and extensive institutional knowledge.  The IQVIA CORE™

About Us

We are IQVIA. The Human Data Science Company.
For the first time ever, the potential of Human Data Science is a reality. Bringing together human data, data science and human science, Human Data Science is a revolutionary new way to harness advances in technology, analytics and, above all, human ingenuity. So our customers can continue their pursuit of improvements in health outcomes.
Global Oncology Trends 2018

Cancer treatments have been advancing at an accelerated pace in recent years, offering notable improvements in clinical benefit to patients. This report highlights advances in cancer therapeutics, including the use of these drugs and their global spending trends, the pipeline of therapeutic innovation and associated clinical trial activity, and the outlook through 2022. The report aims to provide an evidence base that can be used in discussion about the broader implications for cancer patients and their families, providers and their institutions, public and private payers at the local and national level, as well as multinational organizations.